Abbott (ABT) announced clinical data from two presentations at AF Symposium in Boston that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation. The results include 12-month findings that reinforce the long-term safety and performance of Volt Pulsed Field Ablation System. Positive results were also presented on TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy, focal ablation catheter engineered to allow physicians to tailor how they deliver AFib therapy.
The Volt PFA System secured FDA approval and CE Mark in Europe, last year. Commercial cases have begun in the U.S. and expansion in Europe continues.
In pre-market trading on NYSE, Abbott shares are up 0.60 percent to $109.75.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.